查看: 1569|回复: 14
|
【OPTIMAX 0222 交流专区】
[复制链接]
|
|
本帖最后由 icy97 于 21-3-2021 09:00 AM 编辑
(吉隆坡1日讯)专业眼科服务供应商Optimax控股有限公司获得批准上市大马交易所创业板上市,将公开发售7000万新股。
该公司发文告表示,建议发售的新股中,1350万股将供公众申购;400万股让合格董事、员工与对公司有贡献者认购。
余下5250万新股将发售给投资机构和特定投资者。
该公司成立至今已经有25年,在大马拥有13所专科中心。 |
|
|
|
|
|
|
|
楼主 |
发表于 9-7-2020 10:50 AM
|
显示全部楼层
(吉隆坡8日讯)获准在创业板上市的专业眼科服务供应商Optimax控股有限公司,计划于7月15日发出招股书。
该公司已经与艾芬黄氏投资银行签署了股票包销协议。
艾芬黄氏将包销1750万股新股,其中1350万股将供公众认购,其余400万股将分配给合格人士。
Optimax在上市计划下将公开发售7000万股。 |
|
|
|
|
|
|
|
楼主 |
发表于 11-7-2020 08:56 AM
|
显示全部楼层
(吉隆坡10日讯)眼科专科服务供应商Optimax控股,与艾芬黄氏投行有限公司签署包销协议,计划在今年8月18日上市创业板。
Optimax控股日前发布文告指,首次将发行7000万股新股。
新股当中,1350万股供公众认购,400万股供给合格人士认购,其余5250万股将以私下配售方式,供我国机构和指定投资者认购。
根据文告,上市筹资所得,将用作资本开销、偿还贷款、营运资本及上市费用。
其中,资本开销会用来收购森美兰的两栋3层商店或办公室,主要用作门诊中心,及为现有的专科中心购新设备。
总执行长陈欣仪指出,在推行下阶段的业务拓展计划之际,上市计划能巩固公司的财务地位。 |
|
|
|
|
|
|
|
楼主 |
发表于 16-7-2020 08:13 PM
|
显示全部楼层
出席招股书推介礼的也包括Optimax非执行董事拿督陈文福、首席财务员陈欣佳和高级医疗总监张顺习医生(音译)及艾芬黄氏投行副董事经理叶继荣(音译)。
(吉隆坡15日讯)私人眼科专科服务公司Optimax控股今日正式发出招股书以展开首度公开售股(IPO)行动,将从中集资2100万令吉。
该公司计划于下月18日在大马交易所创业板上市。
首席执行员陈欣仪在文告中表示,这次上市是公司成立25年来的重大里程碑。
Optimax控股预计从上市活动中筹集2500万令吉,其中1035万令吉(49.31%)用作资本开销,353万令吉(16.79%)作为营运资本,352万令吉(16.76%)用来还贷款及360万令吉(17.14%)为上市开销。
继续扩张门诊服务中心网络
她表示,公司计划在上市后继续扩张门诊服务中心网络,包括进军新市场。
“首先,我们的即时计划将是扩张中马地区的门诊服务中心网络,以满足这个人口稠密城市社区的潜在需求。”
上市计划中筹集的部份资金将用于装备芙蓉专科中心和购买产业,以将该中心转变为门诊医疗中心。
Optimax控股也计划为现有中心购买新设备和工具,以升级设备、增加服务和扩大产能。
目前该公司拥有13间眼科专科中心,包括一间专科医院,11间门诊护理中心和一间专科诊所,有些是独资拥有,有些则与眼科医生合资。Optimax的专家团队由18名眼科医生和33名验光师组成。
艾芬黄氏投行为该公司上市顾问、配售代理、单一包销商和保荐人。 |
|
|
|
|
|
|
|
楼主 |
发表于 3-8-2020 02:17 PM
|
显示全部楼层
吉隆坡3日讯)大众投资银行研究对预定于8月18日在大马交易所创业板上市的Optimax Holdings Bhd的估值为51仙,这是基于2021财政年每股盈利(4.2仙)的12倍本益比。
Optimax通过13家专科中心,在国内多个州属提供眼科专科服务。
大众投行今日在首次公开募股(IPO)报告中指出,Optimax将继续专注于提供眼科专科服务的核心能力,并扩大国内的地理版图。
Optimax还计划建立更多的门诊护理中心,借助其在提供眼科专科服务方面的现有专业知识。
该研究机构表示,Optimax寻求以2亿7000万股的扩大发行与缴足股本在创业板上市。
该IPO将发行7000万新股,预计筹集约2100万令吉。
大众投行说,除了49.3%的资金将充作资本开销,16.8%将用作营运资本。
根据每股30仙的发行价,该公司上市的市值为8100万令吉。
该机构认为,Optimax的增长将取决于其在大马门诊护理中心网络的扩张,以满足半岛中部地区城市社区的潜在需求。
此外,增长还可能取决于为现有专科中心添置新的眼科设备与工具,以提升现有设备、增加服务范围或扩大现有能力。
“Optimax的竞争优势包括拥有25年的绩效记录、在大马拥有已建立的私人眼科专科中心网络、拥有专业且具有医学资格的眼科医生团队,以及经验丰富的管理与营运团队。”
大众投行强调,主要的需求驱动因素可能包括人口老龄化、人口日益富裕及医疗保健旅游增加等。
而主要下行风险包括同业竞争、依赖消费者情绪与富裕、对一些供应商的依赖、医疗索赔风险、监管行动和专业责任,以及对大马眼科医生的依赖。 |
|
|
|
|
|
|
|
楼主 |
发表于 18-8-2020 11:16 PM
|
显示全部楼层
(吉隆坡18日讯)眼睛专科服务提供商Optimax控股(OPTIMAX,0222,创业板医疗保健)首日挂牌开盘即扬41仙或137%至71仙,对比发售价为30仙,首宗交易约1459万股易手。
Optimax控股盘中最高一度涨46仙或153%,上探76仙,休市时暂挂71仙;该股闭市收涨38.5仙至68.5仙,全日共1亿688万5800股,为20大热门股项之一。
该公司总执行长陈欣怡指出,公司股价的强劲涨势让人出乎意料;Optimax控股计划将集资所得用作营运开销、偿还贷款、支付上市经费等。
她说,公司计划通过将现有的芙蓉专科中心转变为门诊服务中心,扩大门诊服务中心网络,从而满足大马半岛中部地区的需求,并透过添购新设备来提升服务和扩大产能。
“公开上市进一步加强了Optimax控股的形象,使投资者能更充分了解我们的业务。”
截止目前,Optimax控股共有13家眼科专科中心,包括一家专科医院,11家门诊护理中心和一间由常驻眼科医生全资或共同拥有的专科诊所。
“公司近年来发展迅速,2017年在中、南部地区进行了多项收购,如今正式上市所带来的资金将进一步扩大公司的市场范围,并有助实现计划。”
陈欣怡出席上市鸣锣仪式时如事说;今日列席者包括Optimax控股主席兼独立非执行董事丹斯里阿末达祖汀、非独立非执行董事陈文福、主要股东潘斯里林素有、总财务长陈欣佳,以及独立非执行董事叶咏仪和叶斌鸿。 |
|
|
|
|
|
|
|
发表于 13-12-2020 07:48 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31 Mar 2020 |
| INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Mar 2020 | 31 Mar 2019 | 31 Mar 2020 | 31 Mar 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
1 | Revenue | 13,078 | 13,581 | 13,078 | 13,581 | 2 | Profit/(loss) before tax | 1,655 | 2,372 | 1,655 | 2,372 | 3 | Profit/(loss) for the period | 1,107 | 1,744 | 1,107 | 1,744 | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 909 | 1,499 | 909 | 1,499 | 5 | Basic earnings/(loss) per share (Subunit) | 33.67 | 55.52 | 33.67 | 55.52 | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 8.7300 | 8.3900
|
|
|
|
|
|
|
|
|
发表于 15-12-2020 07:13 AM
|
显示全部楼层
Particulars of substantial Securities HolderName | DR CHUNG SOON HEE | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | Ordinary shares | Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | 1 | 18 Aug 2020 | 15,360,000 | Others | Direct Interest | Name of registered holder | DR CHUNG SOON HEE | Description of "Others" Type of Transaction | Refer to remarks |
Circumstances by reason of which change has occurred | Total shares held upon listing of the Company on the ACE Market of Bursa Malaysia Securities Berhad. | Nature of interest | Direct Interest | Direct (units) | 15,360,000 | Direct (%) | 5.689 | Indirect/deemed interest (units) |
| Indirect/deemed interest (%) |
| Total no of securities after change | 15,360,000 | Date of notice | 18 Aug 2020 | Date notice received by Listed Issuer | 18 Aug 2020 |
Name | TAN SRI DATO' TAN BOON HOCK | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | Ordinary Shares | Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | 1 | 18 Aug 2020 | 85,860,000 | Others | Direct Interest | Name of registered holder | TAN SRI DATO' TAN BOON HOCK | Description of "Others" Type of Transaction | Refer to remarks | 2 | 18 Aug 2020 | 78,860,000 | Others | Indirect Interest | Name of registered holder | SENA HEALTHCARE SERVICES SDN BHD (FORMERLY KNOWN AS OPTIMAX HEALTHCARE SERVICES SDN BHD) | Description of "Others" Type of Transaction | Refer to remarks | 3 | 18 Aug 2020 | 1,030,000 | Others | Indirect Interest | Name of registered holder | TAN SING YEE | Description of "Others" Type of Transaction | Refer to remarks | 4 | 18 Aug 2020 | 1,030,000 | Others | Indirect Interest | Name of registered holder | TAN SING CHIA | Description of "Others" Type of Transaction | Refer to remarks |
Circumstances by reason of which change has occurred | Total shares held upon listing of the Company on the ACE Market of Bursa Malaysia Securities Berhad. | Nature of interest | Direct and Indirect Interest | Direct (units) | 85,860,000 | Direct (%) | 31.8 | Indirect/deemed interest (units) | 80,920,000 | Indirect/deemed interest (%) | 29.97 | Total no of securities after change | 166,780,000 | Date of notice | 18 Aug 2020 | Date notice received by Listed Issuer | 18 Aug 2020 |
|
|
|
|
|
|
|
|
发表于 30-12-2020 08:51 AM
|
显示全部楼层
本帖最后由 icy97 于 3-7-2021 11:08 AM 编辑
SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2020 |
| INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Jun 2020 | 30 Jun 2019 | 30 Jun 2020 | 30 Jun 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
1 | Revenue | 9,539 | 16,163 | 22,617 | 29,744 | 2 | Profit/(loss) before tax | 177 | 3,949 | 1,832 | 6,321 | 3 | Profit/(loss) for the period | 118 | 2,709 | 1,225 | 4,453 | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 60 | 2,503 | 969 | 4,002 | 5 | Basic earnings/(loss) per share (Subunit) | 0.03 | 1.25 | 0.48 | 2.00 | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1200 | 0.0000
|
Type | Announcement | Subject | OTHERS | Description | Optimax Holdings Berhad ("Optimax" or "the Company") - Approval from the Ministry of Health of Malaysia (MOH) on the application for an ambulatory care centre licence pursuant to the Private Healthcare Facilities and Services Act 1998 and Private Hospitals and Other Private Healthcare Facilities Regulations 2006 to Optimax Eye Specialist Centre (Seremban) Sdn Bhd, a wholly-owned subsidiary of Optimax. | The Board of Directors of Optimax wishes to announce that Optimax Eye Specialist Centre (Seremban) Sdn Bhd (“OESC Seremban”), a wholly-owned subsidiary of the Company, had on 18 November 2020 received a letter from the MOH dated 13 November 2020 approving OESC Seremban’s application for an ambulatory care centre licence (“Licence”) under the Private Healthcare Facilities and Services Act 1998 and Private Hospitals and Other Private Healthcare Facilities Regulations 2006. The Licence was issued with the aforesaid letter.
The Licence allows OESC Seremban to operate and provide a private ambulatory care centre known as “Optimax Seremban Eye Specialist Centre” situated at No. 141 & 142, Jalan Tun Dr. Ismail, 70200 Seremban, Negeri Sembilan with the following type of healthcare services:
- Ambulatory care services for ophthalmology;
- Nursing and sterilising services; and
- Outpatient specialist services for ophthalmology.
The Licence shall be valid for a period of two (2) years effective from 27 October 2020 to 26 October 2022 and renewable at least six (6) months prior to the expiry of the said Licence.
The Licence will not have any material effect on the earnings per share and net assets per share of the Company and its subsidiaries for the financial year ending 31 December 2020. The Licence will not have any effect on the share capital, gearing and substantial shareholders’ shareholdings of the Company.
This announcement is dated 19 November 2020. |
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2020 |
| INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2020 | 30 Sep 2019 | 30 Sep 2020 | 30 Sep 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
1 | Revenue | 18,192 | 16,069 | 40,809 | 45,813 | 2 | Profit/(loss) before tax | 3,959 | 3,609 | 5,791 | 9,930 | 3 | Profit/(loss) for the period | 2,928 | 2,493 | 4,153 | 6,946 | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 2,595 | 2,239 | 3,564 | 6,241 | 5 | Basic earnings/(loss) per share (Subunit) | 0.96 | 0.83 | 1.32 | 2.31 | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1700 | 0.0000
|
|
|
|
|
|
|
|
|
发表于 8-1-2022 09:10 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2021 |
| INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2021 | 30 Sep 2020 | 30 Sep 2021 | 30 Sep 2020 | $$'000 | $$'000 | $$'000 | $$'000 |
1 | Revenue | 29,769 | 18,192 | 62,291 | 40,809 | 2 | Profit/(loss) before tax | 7,198 | 3,959 | 12,256 | 5,791 | 3 | Profit/(loss) for the period | 5,575 | 2,928 | 9,074 | 4,153 | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 5,415 | 2,595 | 8,728 | 3,564 | 5 | Basic earnings/(loss) per share (Subunit) | 2.01 | 1.20 | 3.23 | 1.65 | 6 | Proposed/Declared dividend per share (Subunit) | 1.90 | 0.00 | 1.90 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.2100 | 0.1800
|
|
|
|
|
|
|
|
|
发表于 8-1-2022 09:27 AM
|
显示全部楼层
Entitlement subject | Interim Dividend | Entitlement description | Interim Single-tier dividend of 1.90 sen per ordinary share | Ex-Date | 09 Dec 2021 | Entitlement date | 10 Dec 2021 | Entitlement time | 5:00 PM | Financial Year End | 31 Dec 2021 | Period |
| Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Payment Date | 24 Dec 2021 | a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers | 10 Dec 2021 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units)
(If applicable) |
| Entitlement indicator | Currency | Announced Currency | Malaysian Ringgit (MYR) | Disbursed Currency | Malaysian Ringgit (MYR) | Entitlement in Currency | Malaysian Ringgit (MYR) 0.0190 |
|
|
|
|
|
|
|
|
发表于 27-2-2022 12:59 AM
|
显示全部楼层
Date of change | 01 Dec 2021 | Name | TAN SRI DATO' DR TAN BOON HOCK | Age | 66 | Gender | Male | Nationality | Malaysia | Type of change | Redesignation | Previous Position | Executive Director | New Position | Executive Deputy Chairman | Directorate | Executive | QualificationsNo | Qualifications | Major/Field of Study | Institute/University | Additional Information |
Working experience and occupation | Tan Sri Dato' Dr Tan Boon Hock ("Tan Sri Dato' Dr Tan") ventured into the eye specialist healthcare industry after incorporating Optimax Eye Specialist Centre Sdn Bhd ("OESC") under the name of Precious Premier (M) Sdn Bhd, offering refractive surgery services to patients. Throughout the 26 years since the incorporation of OESC, Tan Sri Dato' Dr Tan expanded the business of OESC to other states in Malaysia and started providing other eye specialist services, including cataract surgery services.In Tan Sri Dato' Dr Tan's capacity as a director of companies under the Optimax group of companies ("Optimax Group"), he has provided business and management guidance and strategic advice to the senior management of the Optimax Group over the years. He has also played a leading role in the formulation of the business direction and strategies of the Optimax Group. Under his guidance and direction, the Optimax Group has grown rapidly to become one of the major operators in the eye specialist industry in Malaysia. | Family relationship with any director and/or major shareholder of the listed issuer | Tan Sri Dato' Dr Tan, is the father of Ms. Tan Sing Yee, the Chief Executive Officer and Non-Independent Executive Director of the Company and a director and a shareholder of Sena Healthcare Services Sdn Bhd, a major shareholder of the Company. | Any conflict of interests that he/she has with the listed issuer | Nil | Details of any interest in the securities of the listed issuer or its subsidiaries | Direct Interest - 72,043,000 Ordinary SharesIndirect Interest - 81,276,000 Ordinary Shares |
|
|
|
|
|
|
|
|
发表于 4-3-2022 10:06 AM
|
显示全部楼层
Entitlement subject | Bonus Issue | Entitlement description | BONUS ISSUE OF UP TO 67,500,000 WARRANTS IN THE COMPANY ("WARRANT(S)") ON THE BASIS OF ONE (1) WARRANT FOR EVERY FOUR (4) EXISTING ORDINARY SHARES IN OPTIMAX HELD BY ENTITLED SHAREHOLDERS OF THE COMPANY AT 5.00 PM ON 28 DECEMBER 2021 ("BONUS ISSUE OF WARRANTS") | Shareholder's Approval | Yes | Ex-Date | 27 Dec 2021 | Entitlement date | 28 Dec 2021 | Entitlement time | 5:00 PM | Financial Year End | 31 Dec 2021 | Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Securities Crediting Date |
| a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers | 28 Dec 2021 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units)
(If applicable) |
| Entitlement indicator | Ratio | Par Value (if applicable) |
| | Securities Entitlement | Company Name | OPTIMAX HOLDINGS BERHAD | Entitlement | Warrants | Ratio (New : Existing) | 1.0000 : 4.0000 |
|
|
|
|
|
|
|
|
发表于 9-3-2022 09:12 AM
|
显示全部楼层
Type | Announcement | Subject | MEMORANDUM OF UNDERSTANDING | Description | OPTIMAX HOLDINGS BERHAD ("OPTIMAX" OR "THE COMPANY") - MEMORANDUM OF UNDERSTANDING ("MOU") BETWEEN OPTIMAX AND SELGATE HEALTHCARE SDN. BHD. ("SELGATE") | The Board of Directors of Optimax wishes to announce that the Company had on 17 December 2021 entered into a MOU with Selgate to manage and operate a full-service eye specialist centre at the designated Selgate Group of Hospitals on an exclusive basis.
Further details of the above are set out in the attachment.
This announcement is dated 17 December 2021. | https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3219843
|
|
|
|
|
|
|
|
发表于 11-9-2024 08:06 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2024 |
| INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2024 | 30 Jun 2023 | $$'000 | $$'000 | $$'000 | $$'000 |
1 | Revenue | 32,047 | 27,898 | 60,262 | 53,989 | 2 | Profit/(loss) before tax | 5,850 | 5,500 | 10,310 | 10,149 | 3 | Profit/(loss) for the period | 4,202 | 4,184 | 7,526 | 7,499 | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 3,769 | 3,823 | 6,783 | 6,874 | 5 | Basic earnings/(loss) per share (Subunit) | 0.69 | 0.71 | 1.25 | 1.27 | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1200 | 0.1200
|
|
|
|
|
|
|
|
| |
本周最热论坛帖子
|